| Title: |
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. |
| Authors: |
Roccuzzo, Gabriele, Giordano, Silvia, Fava, Paolo, Pileri, Alessandro, Guglielmo, Alba, Tonella, Luca, Sanlorenzo, Martina, Ribero, Simone, Fierro, Maria Teresa, Quaglino, Pietro |
| Source: |
Frontiers in Oncology; 8/16/2021, Vol. 11, p1-10, 10p |
| Subject Terms: |
IMMUNE checkpoint inhibitors, IMMUNE checkpoint proteins, LYMPHOMAS, MYCOSIS fungoides, SURVIVAL rate |
| Company/Entity: |
CHECK Point Software Technologies Ltd. |
| Abstract: |
Primary cutaneous T-cell lymphomas (PCTCL) are the most common types of cutaneous lymphomas, with Mycosis fungoides as the most frequent subtype. Besides early stages which usually have a good prognosis, advanced stages remain a great therapeutic challenge with low survival rates. To date, none of the currently available therapeutic options have significantly improved the outcomes of advanced cutaneous lymphomas. Recent studies have demonstrated that immune-checkpoint molecules, such as PD-1 and CTLA-4, play part in the proliferation pathways of neoplastic T-cells, as well as in other tumors. Hence, the potential role of immune-checkpoint-inhibitors in treating cutaneous lymphomas has been investigated in the last years. Herein, we outline the current knowledge regarding the role of immune-checkpoint molecules in PCTCL, their signaling pathways, microenvironment and therapeutic inhibition rationale. Moreover, we review the published data on immunotherapies in PCTCL and summarize the currently ongoing clinical trials in this field. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
